Navigation Links
Neogen Reactivates Share Repurchase Program
Date:3/9/2009

LANSING, Mich., March 9 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that on March 6 it initiated its current common stock repurchase program. In December, Neogen's Board of Directors authorized the repurchase of up to 500,000 shares.

Shares have been, and additional shares are expected to be, acquired on the open market or in negotiated transactions, depending on market conditions and other factors. Accordingly, there is no guarantee of the exact number of shares to be repurchased. Shares repurchased under the program will be retired. The company had 14,600,000 shares outstanding on Nov. 30, 2008.

"The price of Neogen shares is at the lowest level in nearly two years," said James Herbert, Neogen's CEO. "We believe the price is an extraordinary value given the company's fundamentals and performance that have withstood the worst overall economy in decades."

Neogen's second quarter was the 63rd consecutive profitable quarter from operations for the company, and the 67th quarter of the past 72 quarters to show increased revenues as compared with the previous year--a span of 18 years. Neogen will announce results for the third quarter of its 2009 fiscal year, which ended Feb. 28, on Thursday, March 19.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Webcast Alert: Neogen Corporation To Announce 2nd Quarter Results
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. NeoGenomics to Present at the Noble Financial Equity Conference
5. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
6. NeoGenomics Announces Results for the 3rd Quarter 2007
7. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
8. Stimulating Thymus Reactivates T-Cell Production
9. Consumer Group Wants Public to Share Profits From Federally Funded Stem Cell and Medical Research
10. Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger
11. Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology: